scholarly journals Peripheral Edema Occurring during Treatment with Risperidone Combined with Citalopram

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Seyed Hamzeh Hosseini ◽  
Amirhossein Ahmadi

An 80-year-old female presented with symptoms of depression, worthlessness, hopelessness, loss of energy, insomnia, impatience, and forgetfulness associated with persecutory delusion that had begun about one year before her visit. She was diagnosed with major depression with psychotic signs and began treatment with risperidone (2 mg/night) and citalopram (20 mg/day). After 20 days, she returned and reported partial improvement in her symptoms, although she had developed severe swelling of the hands and feet. The results of liver and renal function tests and rheumatologic tests were found to be within normal limits. Risperidone was discontinued for a week, and the swelling resolved completely. Risperidone was then administered again, and the swelling returned so that the patient had to discontinue taking the drug. The reappearance of edema on rechallenge is strong evidence implicating risperidone as the cause of the swelling.

2021 ◽  
pp. jnmt.121.262462
Author(s):  
Jan-Henning Schierz ◽  
ismet sarikaya ◽  
Ahmed N Albatineh ◽  
Ali Sarikaya

1995 ◽  
Vol 43 (4) ◽  
pp. 412-414 ◽  
Author(s):  
Donald A. Feinfeld ◽  
Howard Guzik ◽  
Christos P. Carvounis ◽  
Robert I. Lynn ◽  
Bradley Somer ◽  
...  

2021 ◽  
Vol 74 (10) ◽  
pp. 2460-2462
Author(s):  
Seher Abdurasool Almedeny ◽  
Jabbar Yasir AL- Mayah ◽  
Mohanmed S. Abdulzahra ◽  
Najah R. Hadi

The aim: To evaluate the effect of single daily 25 mg of spironolactone on serum electrolytes and kidney function tests in patients with severe chronic left sided heart failure. Materials and methods: 60 patients with severe chronic left sided heart failure were enrolled in this study and they were divided in to 2 equal groups’ one group with standard therapy of HF and the other with spironolactone in a dose of 25 mg / day, as an additive therapy to the standard one. Serum electrolytes and kidney function tests were assessed at the beginning of the study and after 3 months. Results: A significant increment in serum potassium (p<0.05) was observed in the spironolactone group after 3 months treatment, while no significant reduction in serum sodium (p>0.05) and no significant increase in serum creatinine and blood urea (p>0.05) was noticed in the same group, control group showed no significant changes (p>0.05), in both serum electrolytes (S.K and S.Na) and renal function tests (S.C and B.U). Conclusions: Spironolactone caused a significant elevation of serum potassium level but this elevation is still with the clinically accepted ranges when low dose of spironolactone is used and with intact renal function. Serum creatinine level was not significantly increased with 25 mgl day of spironolactone. We conclude that Renal function tests namely blood urea and serum Creatinine, and serum potassium should be closely monitored in patients on spironolactone therapy especially those patients who use ACEI and ARBs in addition.


Sign in / Sign up

Export Citation Format

Share Document